Our proprietary hemodiafiltration   
     technologies can improve
     treatment efficacy by 80% and
     more.

     Nephros Technology offers:
   

    >   Reduced patient morbidity,
         with reduced drug usage and
         potentially reduced hospital
         admissions.
   
    >   Improved treatment quality
         providing an improvement in         
         marked improvement in the
         patient's quality of life.



Nephros,  Inc.  was   founded  in  1997  by  Columbia  University  health
for  the  End Stage  Renal  Disease  (ESRD)  patient,  while  addressing
the  critical  needs  of  the  care  provider. The Company has developed
the most effective  ESRD  therapy  available  worldwide, offering unique
and proprietary  technologies that  dramatically improve clinical efficacy.
Nephros technologies  also  remove a range of harmful substances  not
currently removed  by  existing  dialysis methods; addressed specifically
are substances known collectively  as  middle  molecules,  due  to  their
molecular  weight,  that  contribute  to  such  conditions as carpal tunnel
syndrome, dialysis related amyloidosis, and degenerative bone disease
in the ESRD patient.

Founded in 1997 to address current voids in ESRD treatment:

  • Stale Methodologies
  • Cost and Reimbursement Issues
  • Quality of Care Issues
Nephros technology focus:
  • Unique and cost-effective proprietary technologies
  • Marked improvements in treatment efficacy per unit time
  • Platforms: easy to use and maintain
  • Technology that integrates well with existing mfg and clinical
    infrastructures
Email Alerts
© 2009 Nephros, Inc                                                   Powered by Advisions